Atrial Fibrillation Market to Register Sustainable Growth During the Forecast Period (2023-2032) – DelveInsight | Vivasc, ARCA Biopharma, Hyloris, Anthos Therapeutics, Milestone Pharma, Hanmi Pharma

Atrial Fibrillation Market to Register Sustainable Growth During the Forecast Period (2023-2032) - DelveInsight | Vivasc, ARCA Biopharma, Hyloris, Anthos Therapeutics, Milestone Pharma, Hanmi Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Atrial Fibrillation Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies and the increasing prevalence of atrial fibrillation in the 7MM.

DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Atrial Fibrillation market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Atrial Fibrillation drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Atrial Fibrillation treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Atrial Fibrillation: An Overview

Atrial fibrillation, often called AFib or AF, is the leading cardiac cause of stroke and is the most common type of cardiac arrhythmia. It is characterized by rapid and irregular beating of the atrial chambers of the heart, due to abnormal electrical activity, because of which the blood doesn’t flow as well as it should from the atria to the two ventricles. This lack of coordination between the upper and lower chambers causes irregular heartbeat.

Either the disease may be episodic, or a permanent condition and can begin as an atrial flutter that transforms into AF. Any condition that leads to inflammation, stress, damage, or ischemia affecting the anatomy of the heart can result in the development of atrial fibrillation. In some cases, the cause is iatrogenic.

The three patterns of atrial fibrillation include paroxysmal, which occurs spontaneously and generally resolves by itself or with treatment within seven days, and persistent, which is for more than seven days and needs either pharmacological or electrical cardioversion. It might lead to electrical remodeling in the cardiac myocytes causing dilated cardiomyopathy and is usually a result of recurrent episodes of paroxysmal AF. The third is long-standing persistent AF that has been present for more than 12 months, either due to the failure of initiation of pharmacological intervention or failure of cardioversion. Permanent AF is where a decision has been made to abort all therapies because the rhythm is unresponsive.

Atrial Fibrillation Market Key Facts

  • According to the study conducted by Rosenthal et al. (2016), Atrial Fibrillation is the most frequently encountered cardiac arrhythmia. It affects more than 2.7 to 6.1 million persons in the United States. AF is strongly age-dependent, affecting 4% of individuals older than 60 years and 8% of persons older than 80 years. Approximately 25% of individuals aged 40 years and older will develop AF during their lifetime.

  • According to the Centers for Disease Control and Prevention (2022), it is estimated that 12.1 million people in the US will have AF in 2030. In 2019, AF was mentioned on 183,321 death certificates and was the underlying cause of death in 26,535 of those deaths. Further, more than 454,000 hospitalizations with AF as the primary diagnosis happen each year in the US, and the condition contributes to about 158,000 deaths each year.

  • As per the study by Velleca et al. (2018), currently, >11 million patients are estimated to have AF in Europe, and the total healthcare costs of AF account for ≤2.6% of total healthcare expenditure in Europe. Over 1 million people are afflicted by AF in each of France, Germany, Italy, and the UK. 

Atrial Fibrillation Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Atrial Fibrillation pipeline therapies. It also thoroughly assesses the Atrial Fibrillation market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Atrial Fibrillation drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Atrial Fibrillation Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Atrial Fibrillation epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Atrial Fibrillation epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Atrial Fibrillation Epidemiology, Segmented as –

  • Total Prevalent Cases of Atrial Fibrillation

  • Diagnosed and Treatable cases of Atrial Fibrillation

  • Gender-specific Prevalent cases of Atrial Fibrillation

  • Age-specific Prevalent cases of Atrial Fibrillation

  • Type-specific cases of Atrial Fibrillation

Atrial Fibrillation Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Atrial Fibrillation market or expected to be launched during the study period. The analysis covers the Atrial Fibrillation market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Atrial Fibrillation drugs based on their sale and market share.

The report also covers the Atrial Fibrillation pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Atrial Fibrillation companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Atrial Fibrillation Market Will Evolve and Grow by 2032 @

Atrial Fibrillation Therapeutics Analysis

The cornerstones of Atrial Fibrillation (AFib) management are Rate Control, Anticoagulation, and Rhythm Control for those symptomatically limited by AF. The clinical decision to use a rhythm-control or rate-control strategy requires an integrated consideration of several factors, including degree of symptoms, likelihood of successful cardioversion, presence of comorbidities, and candidacy for AFib ablation. Warfarin represents the cornerstone of anticoagulant therapy for patients at moderate to high risk of thromboembolic events. 

Some patients may not be able to take anticoagulants because of contraindications or comorbidities. The goal of antiarrhythmic drug therapy is to reduce the duration and frequency of atrial fibrillation episodes, thus improving the patient’s quality of life and symptoms. If successful, rhythm control can eliminate or delay the need for long-term anticoagulation with warfarin in some patients. Several antiarrhythmic drugs are commonly used to prevent atrial fibrillation recurrence, such as quinidine, flecainide, propafenone, sotalol, and dofetilide. Other antiarrhythmic agents, such as amiodarone, are used in an off-label fashion with great clinical efficacy.

There is a significant need for safer and more effective pharmacological interventions to treat atrial fibrillation, as current treatments have poor safety and efficacy profiles, and the alternative, electrical cardioversion, has poor patient acceptance and requires patient sedation.

Several major pharma and biotech companies are developing therapies for Atrial Fibrillation. Currently, Anthos Therapeutics is leading the therapeutics market with its Atrial Fibrillation drug candidates in the most advanced stage of clinical development.

Atrial Fibrillation Companies Actively Working in the Therapeutics Market Include

  • ARCA biopharma Inc

  • Anthos Therapeutics, Inc.

  • Milestone Pharmaceuticals

  • Armaron Biosciences

  • Ono Pharmaceutical

  • Hanmi Pharmaceutical

  • HUYA Bioscience International

  • Hyloris Pharmaceuticals

  • Vivasc Therapeutics

  • Espero BioPharma

And Many Others

Emerging and Marketed Atrial Fibrillation Therapies Covered in the Report Include:

  • Abelacimab: Anthos Therapeutics, Inc.

  • Etripamil: Milestone Pharmaceuticals

  • GENCARO: ARCA biopharma

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Atrial Fibrillation Competitive Intelligence Analysis

4. Atrial Fibrillation Market Overview at a Glance

5. Atrial Fibrillation Disease Background and Overview

6. Atrial Fibrillation Patient Journey

7. Atrial Fibrillation Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Atrial Fibrillation Treatment Algorithm, Current Treatment, and Medical Practices

9. Atrial Fibrillation Unmet Needs

10. Key Endpoints of Atrial Fibrillation Treatment

11. Atrial Fibrillation Marketed Therapies

12. Atrial Fibrillation Emerging Drugs and Latest Therapeutic Advances

13. Atrial Fibrillation Seven Major Market Analysis

14. Attribute Analysis

15. Atrial Fibrillation Market Outlook (In US, EU5, and Japan)

16. Atrial Fibrillation Companies Active in the Market

17. Atrial Fibrillation Access and Reimbursement Overview

18. KOL Views on the Atrial Fibrillation Market

19. Atrial Fibrillation Market Drivers

20. Atrial Fibrillation Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Primary Progressive Multiple Sclerosis (PPMS) Market

“Primary Progressive Multiple Sclerosis (PPMS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Primary Progressive Multiple Sclerosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States